NEW YORK, Sept. 18 - Genomatica is developing an in silico model for Dow Chemical to predict the effect of genetic changes on microbial metabolism and bioprocessing, the companies announced today.
Genomatica, based in San Diego, will use its SimPheny platform to develop the modeling for Dow, according to the company.
Financial details of the agreement were not disclosed, though the company said Dow would provide research support and milestone payments.